Stocks, gold and silver steady following more wild swings in markets overnight  WRAL

Palmetto Grain Brokerage -  Palmetto Grain Brokerage

* Stock Market Today: Dow up nearly 300 points, S&P 500 and Nasdaq shake off earlier weakness in morning action as tech stocks stabilize. Oil slumps, while gold is steady.  MarketWatch * Stock market today: Dow, S&P 500, Nasdaq futures plunge ahead of week defined by Trump's Fed pick, jobs data  Yahoo Finance UK * Stock Market Today: Dow, S&P 500, Nasdaq Open Lower; Palantir, SoFi, Tesla, Nvidia, More Movers; Gold, Bitcoin Drop  Barron's

WASHINGTON, Feb 2 (Reuters) - U.S. immigration officials have quarantined some migrants and halted "all movement" after two measles cases were confirmed among detainees at its facility in south Texas, the Department of Homeland Security said on Monday. The cases at Dilley Immigration Processing Center were confirmed by the state’s health department on Saturday, DHS said in a statement, adding that "all detainees are being provided with proper medical care." "ICE Health Services Corps immediately took steps to quarantine and control further spread and infection, ceasing all movement within the facility and quarantining all individuals suspected of making contact with the infected," the department added. "Medical staff is continuing to monitor the detainees’ conditions and will take appropriate and active steps to prevent further infection." The two Texas cases come amid rising measles cases across the country, including elsewhere in the state and in South Carolina, which has seen the biggest state-level outbreak so far with 789 infections. Texas led a surge in measles cases nationally in 2025 with 762 infections mostly in the west, with the United States recording its largest outbreak since the disease was declared eliminated from the country in 2000. The state’s outbreak was declared over in August. ICE’s Dilley facility, operated by the private company CoreCivic, was opened in 2014 to house migrant families caught crossing the U.S.-Mexico border illegally. It had been due to close under the Biden administration but was since recontracted under ICE last year under U.S. President Donald Trump as part of his immigration crackdown. What are the best investment opportunities in 2026? The best investments start with better data. Going with your gut has its place, but when excitement masquerades as intuition, it can lead to costly mistakes—or analysis paralysis. InvestingPro+ combines institutional-grade data with AI-powered insights that you don't need a finance PhD to understand. It won't guarantee winners, but it will certainly help you find more of them, more often. So what are the best investments of 2026 so far?

Futures fell before Monday's open with the major indexes testing key levels amid a risk-off shift. Disney, Palantir, Oracle and Tesla are early movers. The post Stock Market Today: Dow Futures Steady; Disney, Palantir, Oracle, Tesla Are Early Market Movers (Live Coverage) appeared first on Investor's Business Daily.

Tesla Profit Forecasts Slashed Amid Musk's Spending Spree  Investor's Business Daily

Trump Wants a Critical Minerals Stockpile, Report Says. What It Means for MP, Peer Stocks.  Barron's

3 Promising UK Penny Stocks With Over £20M Market Cap  Yahoo Finance

A $3 Trillion Market Opportunity: My Top AI Stock to Buy in February  Yahoo Finance

5 Things to Know Before the Stock Market Opens  Investopedia

Stock Market Today: Nasdaq Futures Fall; Gold, Silver Prices in Focus — Live Updates  The Wall Street Journal

Investing.com -- MoonLake Immunotherapeutics (NASDAQ:MLTX) stock jumped 6.5% in premarket trading Monday after the company announced that the FDA has granted Fast Track designation to its sonelokimab (SLK) treatment for moderate-to-severe palmoplantar pustulosis (PPP). The regulatory decision follows positive results from the Phase 2 LEDA trial and comes after recent FDA guidance confirming the company’s clinical evidence strategy for a planned Biologic License Application (BLA) submission for SLK in hidradenitis suppurativa (HS) in the second half of 2026. Fast Track designation is designed to facilitate development and expedite review of drugs that treat serious conditions with unmet medical needs. For MoonLake, this means more frequent FDA interactions, potential eligibility for Accelerated Approval and Priority Review, and the ability to submit completed BLA sections on a rolling basis. "This FDA decision marks an important milestone for MoonLake and for patients living with PPP," said Dr. Jorge Santos da Silva, Founder and CEO of MoonLake Immunotherapeutics. "It underscores the significant unmet need in this debilitating disease and SLK’s potential to address it." The clinical-stage biotechnology company, which focuses on developing treatments for inflammatory diseases, also announced an upcoming Investor Day webcast scheduled for February 23, 2026. During this event, the company plans to present the Phase 2 S-OLARIS readout in axial spondyloarthritis (axSpA), discuss FDA feedback on hidradenitis suppurativa, and outline key catalysts for 2026. MoonLake’s upcoming milestones include the primary endpoint readout of the Phase 2 S-OLARIS trial in axSpA in February 2026, 52-week data from VELA trials in HS in Q2 2026, and primary endpoint readouts for Phase 3 trials in psoriatic arthritis and adolescent HS in mid-2026. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. ProPicks AI evaluates MLTX alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if MLTX is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?